Edward F. Webb

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung

David C. Underwood, Ruth R. Osborn, Steven Bochnowicz et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2000 · 298 citations

Medicine, Pathobiology, Pharmacology +17

SB 239063, a Potent p38 MAP Kinase Inhibitor, Reduces Inflammatory Cytokine Production, Airways Eosinophil Infiltration, and Persistence

David C. Underwood, Ruth R. Osborn, Charles J. Kotzer et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 244 citations

Medicine, Immunology, Pharmacology +15

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

Alison M. Badger, Don E. Griswold, Rasesh Kapadia et al. · Arthritis & Rheumatism · 2000 · 219 citations

Medicine, Immunology, Pharmacology +17

Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes

Jerry L. Adams, Jeffrey C. Boehm, Shouki Kassis et al. · Bioorganic & Medicinal Chemistry Letters · 1998 · 113 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Nonpeptide Tachykinin Receptor Antagonists: I. Pharmacological and Pharmacokinetic Characterization of SB 223412, a Novel, Potent and Selective Neurokinin-3 Receptor Antagonist

Henry M. Sarau, Don E. Griswold, W. M. Potts et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 107 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10